Biotechnology Having just last month become the first company to get US approval in the therapy class, UK pharma major GSK revealed that US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of it Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making. 22 June 2023